Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [68Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
2.1. Characteristics of Patients
2.2. Inter-Reader Agreement
2.3. Lesion Analysis
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. [68Ga]Ga-PSMA-11 PET/MRI Imaging Protocol
4.3. Image Analysis
4.4. Statistical Analysis
5. Limitations
6. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Abbreviations
ADC | apparent diffusion coefficient |
ADT | Androgen deprivation therapy |
BPH | Benign prostatic hyperplasia |
CI | Confidence interval |
CT | Computed tomography |
DCE-MRI | Dynamic contrast-enhanced MRI |
DWI | Diffusion-weighted imaging |
IQR | Interquartile range |
FOV | Field-of-view |
Ga | Gallium |
GS | Gleason score |
LBR | Lesion-to-background ratio |
MRI | Magnetic resonance imaging |
mpMRI | Multiparametric magnetic resonance imaging |
OSEM | Ordered subset expectation maximization algorithm |
PCa | Prostate cancer |
PET/CT | Positron emission tomography/computed tomography |
PET/MR | Positron emission tomography /magnetic resonance |
PI-RADS | Prostate Imaging Reporting and Data System |
PSA | Prostate-specific antigen |
PSMA | Prostate-specific membrane antigen |
PROMISE | Prostate Cancer Molecular Imaging Standardized Evaluation |
ROI | Region of interest |
RP | Radical prostatectomy |
SUV | Standardized uptake value |
TE | Echo time |
TR | Repetition time |
T2WI | T2-weighted imaging |
References
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 2018, 60, 277–300. [Google Scholar] [CrossRef] [PubMed]
- Muller, B.G.; Shih, J.H.; Sankineni, S.; Marko, J.; Rais-Bahrami, S.; George, A.K.; De La Rosette, J.J.M.C.H.; Merino, M.J.; Wood, B.J.; Pinto, P.A.; et al. Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. Radiology 2015, 277, 741–750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weinreb, J.C.; Barentsz, J.O.; Choyke, P.L.; Cornud, F.; Haider, M.A.; Macura, K.J.; Margolis, D.J.A.; Schnall, M.D.; Shtern, F.; Tempany, C.M.; et al. PI-RADS Prostate Imaging—Reporting and Data System: 2015, Version 2. Eur. Urol. 2016, 69, 16–40. [Google Scholar] [CrossRef] [PubMed]
- Rosenkrantz, A.B.; Ginocchio, L.A.; Cornfeld, D.; Froemming, A.T.; Gupta, R.T.; Turkbey, B.; Westphalen, A.C.; Babb, J.S.; Margolis, D.J. Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. Radiology 2016, 280, 793–804. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Borofsky, S.; George, A.K.; Gaur, S.; Bernardo, M.; Greer, M.; Mertan, F.V.; Taffel, M.; Moreno, V.; Merino, M.J.; Wood, B.J.; et al. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology 2018, 286, 186–195. [Google Scholar] [CrossRef]
- Rosenkrantz, A.B.; Babb, J.S.; Taneja, S.S.; Ream, J.M. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection. Radiology 2017, 283, 119–129. [Google Scholar] [CrossRef]
- Benndorf, M.; Hahn, F.; Krönig, M.; Jilg, C.A.; Krauss, T.; Langer, M.; Dovi-Akué, P. Diagnostic performance and reproducibility of T2w based and diffusion weighted imaging (DWI) based PI-RADSv2 lexicon descriptors for prostate MRI. Eur. J. Radiol. 2017, 93, 9–15. [Google Scholar] [CrossRef]
- Benndorf, M.; Waibel, L.; Krönig, M.; Jilg, C.A.; Langer, M.; Krauss, T. Peripheral zone lesions of intermediary risk in multiparametric prostate MRI: Frequency and validation of the PI-RADSv2 risk stratification algorithm based on focal contrast enhancement. Eur. J. Radiol. 2018, 99, 62–67. [Google Scholar] [CrossRef]
- Ross, J.S.; Sheehan, C.E.; Fisher, H.A.G.; Kaufman, R.P.; Kaur, P.; Gray, K.; Webb, I.; Gray, G.S.; Mosher, R.; Kallakury, B.V.S. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 2003, 9, 6357–6362. [Google Scholar]
- Treglia, G.; Annunziata, S.; Pizzuto, D.A.; Giovanella, L.; Prior, J.O.; Ceriani, L. Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. Cancers 2019, 11, 710. [Google Scholar] [CrossRef] [Green Version]
- Koerber, S.A.; Utzinger, M.T.; Kratochwil, C.; Kesch, C.; Haefner, M.F.; Katayama, S.; Mier, W.; Iagaru, A.H.; Herfarth, K.; Haberkorn, U.; et al. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. J. Nucl. Med. 2017, 58, 1943–1948. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Woythal, N.; Arsenic, R.; Kempkensteffen, C.; Miller, K.; Janssen, J.-C.; Huang, K.; Makowski, M.R.; Brenner, W.; Prasad, V. Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer. J. Nucl. Med. 2018, 59, 238–243. [Google Scholar] [CrossRef] [Green Version]
- Zamboglou, C.; Drendel, V.; Jilg, C.A.; Rischke, H.C.; Beck, T.I.; Schultze-Seemann, W.; Krauss, T.; Mix, M.; Schiller, F.; Wetterauer, U.; et al. Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics 2017, 7, 228–237. [Google Scholar] [CrossRef]
- Eiber, M.; Weirich, G.; Holzapfel, K.; Souvatzoglou, M.; Haller, B.; Rauscher, I.; Beer, A.J.; Wester, H.-J.; Gschwend, J.; Schwaiger, M.; et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur. Urol. 2016, 70, 829–836. [Google Scholar] [CrossRef]
- Turkbey, B.; Rosenkrantz, A.B.; Haider, M.A.; Padhani, A.R.; Villeirs, G.; Macura, K.J.; Tempany, C.M.; Choyke, P.L.; Cornud, F.; Margolis, D.J.; et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur. Urol. 2019, 76, 340–351. [Google Scholar] [CrossRef]
- Ben Jemaa, A.; Bouraoui, Y.; Sallami, S.; Banasr, A.; Nouira, Y.; Horchani, A.; Oueslati, R. Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer. Tunis Med. 2013, 91, 458–463. [Google Scholar]
- Eiber, M.; Fendler, W.P.; Rowe, S.P.; Calais, J.; Hofman, M.S.; Maurer, T.; Schwarzenboeck, S.M.; Kratowchil, C.; Herrmann, K.; Giesel, F.L. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J. Nucl. Med. 2017, 58 (Suppl. 2), 67S–76S. [Google Scholar] [CrossRef] [Green Version]
- Lapidus, R.G.; Tiffany, C.W.; Isaacs, J.T.; Slusher, B.S. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 2000, 45, 350–354. [Google Scholar] [CrossRef]
- Westphalen, A.C.; McCulloch, C.E.; Anaokar, J.M.; Arora, S.; Barashi, N.S.; Barentsz, J.O.; Bathala, T.K.; Bittencourt, L.K.; Booker, M.T.; Braxton, V.G.; et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology 2020, 296, 76–84. [Google Scholar] [CrossRef]
- Tamada, T.; Kido, A.; Takeuchi, M.; Yamamoto, A.; Miyaji, Y.; Kanomata, N.; Sone, T. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer. Eur. J. Radiol. 2019, 121, 108704. [Google Scholar] [CrossRef]
- Byun, J.; Park, K.J.; Kim, M.; Kim, J.K. Direct Comparison of PI-RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancer: Preliminary Experience. J. Magn. Reson. Imaging 2020, 52, 577–586. [Google Scholar] [CrossRef] [PubMed]
- Wei, C.-G.; Zhang, Y.-Y.; Pan, P.; Chen, T.; Yu, H.-C.; Dai, G.-C.; Tu, J.; Yang, S.; Zhao, W.-L.; Shen, J. Diagnostic Accuracy and Inter-observer Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers. Am. J. Roentgenol. 2020. [Google Scholar] [CrossRef]
- Barrett, T.; Rajesh, A.; Rosenkrantz, A.; Choyke, P.; Turkbey, B. PI-RADS version 2.1: One small step for prostate MRI. Clin. Radiol. 2019, 74, 841–852. [Google Scholar] [CrossRef]
- Bettermann, A.S.; Zamboglou, C.; Kiefer, S.; Jilg, C.A.; Spohn, S.; Kranz-Rudolph, J.; Fassbender, T.F.; Bronsert, P.; Nicolay, N.H.; Gratzke, C.; et al. [68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard—Implications for focal radiotherapy planning in primary prostate cancer. Radiother. Oncol. 2019, 141, 214–219. [Google Scholar] [CrossRef]
- Zamboglou, C.; Wieser, G.; Hennies, S.; Rempel, I.; Kirste, S.; Soschynski, M.; Rischke, H.C.; Fechter, T.; Jilg, C.A.; Langer, M.; et al. MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2015, 43, 889–897. [Google Scholar] [CrossRef]
- Garzón, J.G.; Torres, M.D.A.; Delgado-Bolton, R.C.; Ceci, F.; Ruiz, S.A.; Rincón, J.O.; Caresia-Aróztegui, A.P.; Garcia-Velloso, M.J.; Vicente, A.G. 68Ga-PSMA PET/CT in prostate cancer. Rev. Esp. Med. Nucl. Imagen. Mol. 2018, 37, 130–138. [Google Scholar] [CrossRef]
- Corfield, J.; Perera, P.M.S.; Bolton, D.; Lawrentschuk, N. 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: A systematic review. World J. Urol. 2018, 36, 519–527. [Google Scholar] [CrossRef] [PubMed]
- Nanabala, R.; Anees, M.K.; Sasikumar, A.; Joy, A.; Pillai, M. Preparation of [68Ga]PSMA-11 for PET–CT imaging using a manual synthesis module and organic matrix based 68Ge/68Ga generator. Nucl. Med. Biol. 2016, 43, 463–469. [Google Scholar] [CrossRef] [PubMed]
- Hope, T.A.; Aggarwal, R.; Chee, B.; Tao, D.; Greene, K.L.; Cooperberg, M.R.; Feng, F.; Chang, A.; Ryan, C.J.; Small, E.J.; et al. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J. Nucl. Med. 2017, 58, 1956–1961. [Google Scholar] [CrossRef] [Green Version]
- Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.G.; Hadaschik, B.A.; Holland-Letz, T.; Giesel, F.L.; Kratochwil, C.; Haufe, S.; et al. PET imaging with a 68Gagallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 486–495. [Google Scholar] [CrossRef]
- Landis, J.R.; Koch, G.G. The Measurement of Observer Agreement for Categorical Data. Biometrics 1977, 33, 159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Characteristics | N = 46 |
---|---|
Age at scan (years) | 75 ± 7 |
PSA (ng/mL) at scan time | 12.48 (4.33, 26.48) |
Primary tumor stage (n) | |
≤ cT2c | 16 (35%) |
≥ cT3a | 30 (65%) |
Primary lymph node stage (n) | |
cN0 | 25 (54%) |
cN1 | 21 (46%) |
Biopsy Gleason score (n) | |
3 + 3 | 10 (22%) |
3 + 4 | 9 (19%) |
4 + 3 | 7 (15%) |
4 + 4 | 10 (22%) |
4 + 5 | 3 (7%) |
5 + 4 | 5 (11%) |
5 + 5 | 2 (4%) |
Treatment | |
ADT prior to scan (n) | 2 (4%) |
ADT ongoing at the time of scan (n) | 9 (19%) |
Radiotherapy prior to scan (n) | 8 (17%) |
PI-RADS | Version 2.0 (n) | SUVmax | LBR of SUVmax | Version 2.1 (n) | SUVmax | LBR of SUVmax | SUVmax p Value | LBR p Value |
---|---|---|---|---|---|---|---|---|
1 | 12 | 1.1 (0.4, 1.7) | 1.2 (0.5, 1.9) | 21 | 1.5 (0.5, 1.9) | 1.4 (0.7, 2.1) | p = 0.02 | p = 0.02 |
2 | 34 | 2.4 (1.3, 3.2) | 2.1 (1.5, 2.9) | 21 | 1.9 (0.8, 2.3) | 1.6 (0.9, 2.4) | p = 0.02 | p = 0.02 |
3 | 25 | 3.1 (2.1, 4.4) | 2.5 (1.5, 3.5) | 29 | 3.3 (2.1, 4.6) | 2.6 (1.5, 3.6) | p = 0.73 | p = 0.84 |
4 | 26 | 4.2 (3.1, 5.7) | 3.4 (2.5, 4.8) | 26 | 4.2 (3.1, 5.7) | 3.4 (2.5, 4.8) | p = 1 | p = 1 |
5 | 28 | 7.3 (5.2, 9.7) | 6.8 (3.3, 12.8) | 28 | 7.3 (5.2, 9.7) | 6.8 (3.3, 12.8) | p = 1 | p = 1 |
PI-RADS | Version 2.0 (n) | SUVmax | LBR of SUVmax | Version 2.1 (n) | SUVmax | LBR of SUVmax | SUVmax p Value | LBR p Value |
---|---|---|---|---|---|---|---|---|
1 | 14 | 1.0 (0.8, 1.6) | 1.1 (0.4, 1.8) | 14 | 1.0 (0.8, 1.6) | 1.1 (0.4, 1.8) | p = 1 | p = 1 |
2 | 15 | 2.5 (1.3, 3.3) | 2.1 (1.5, 2.9) | 18 | 2.5 (1.5, 3.2) | 2.2 (1.6, 2.9) | p = 0.81 | p = 0.86 |
3 | 18 | 3.1 (2.0, 4.5) | 2.5 (1.5, 3.5) | 13 | 3.3 (1.9, 4.5) | 2.6 (1.5, 3.6) | p = 0.85 | p = 0.87 |
4 | 18 | 4.3 (2.9, 5.4) | 3.8 (2.7, 4.4) | 20 | 4.3 (3.0, 5.4) | 3.8 (2.8, 4.8) | p = 0.92 | p = 0.95 |
5 | 25 | 7.4 (5.0, 9.3) | 6.9 (3.1, 11.9) | 25 | 7.4 (5.0, 9.3) | 6.9(3.1, 11.9) | p = 1 | p = 1 |
Sequence | TR/TE (ms) | FOV (mm) | Flip Angle (degrees) | Section Thickness (mm) | Voxel Size (mm) |
---|---|---|---|---|---|
T2WI HASTE Axial | 1400.0/95.0 | 400 | 160 | 5.0 | 1.3 × 1.3 × 5.0 |
T1WI FS VIBE | 1600.0/96.0 | 350 | 160 | 4.0 | 1.1 × 1.1 × 4.0 |
T2WI Axial | 5500.0/103.0 | 180 | 150 | 3.0 | 0.5 × 0.5 × 3.0 |
T2WI Sagittal | 1600.0/96.0 | 350 | 160 | 4.0 | 1.1 × 1.1 × 4.0 |
T2WI Coronal | 4500.0/102.0 | 200 | 173 | 3.0 | 0.4 × 0.4 × 3.0 |
DWI | 11,600.0/70.0 | 280 | 3.0 | 2.5 × 2.5 × 3.0 | |
T1WI FS TWIST dynamic | 7.41/3.30 | 260 | 12 | 3.5 | 1.4 × 1.4 × 3.5 |
T1WI STARVIBE | 3.71/1.77 | 360 | 9 | 1.2 | 1.1 × 1.1 × 1.2 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zhao, J.; Mangarova, D.B.; Brangsch, J.; Kader, A.; Hamm, B.; Brenner, W.; Makowski, M.R. Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [68Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1. Cancers 2020, 12, 3523. https://doi.org/10.3390/cancers12123523
Zhao J, Mangarova DB, Brangsch J, Kader A, Hamm B, Brenner W, Makowski MR. Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [68Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1. Cancers. 2020; 12(12):3523. https://doi.org/10.3390/cancers12123523
Chicago/Turabian StyleZhao, Jing, Dilyana B. Mangarova, Julia Brangsch, Avan Kader, Bernd Hamm, Winfried Brenner, and Marcus R. Makowski. 2020. "Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [68Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1" Cancers 12, no. 12: 3523. https://doi.org/10.3390/cancers12123523